Ariamala Gopalsamy

Ariamala Gopalsamy

Auto-generated profile, based on publicly available information

Ariamala Gopalsamy

Oncology R&D, AstraZeneca, Waltham, MA, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
OFOlugbeminiyi O. Fadeyi
Olugbeminiyi O. Fadeyi
LHLise R. Hoth
Lise R. Hoth
CCChulho Choi
Chulho Choi
XFXidong Feng
Xidong Feng
AGAriamala Gopalsamy
Ariamala Gopalsamy
LJLyn H. Jones
Lyn H. Jones

3 June 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAriamala Gopalsamy
Ariamala Gopalsamy

16 March 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAriamala Gopalsamy
Ariamala Gopalsamy
ANArjun Narayanan
Arjun Narayanan
SLShenping Liu
Shenping Liu
MPMihir D. Parikh
Mihir D. Parikh
RKRobert E. Kyne
Robert E. Kyne
LJLyn H. Jones
Lyn H. Jones

2 April 2024 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
ELEsther C. Y. Lee
Esther C. Y. Lee
KRKyle D. Reichl
Kyle D. Reichl
AGAriamala Gopalsamy
Ariamala Gopalsamy
SMARCA2 and SMARCA4 are subunits of the SWI/SNF complex which is a chromatin remodeling complex and a key epigenetic regulator that facilitates gene expression. Tumors with loss of function mutations in SMARCA4 rely on SMARCA2 for cell survival and this synthetic lethality is a potential therapeutic strategy to treat cancer. The current review focuses on patent applications that claim proteolysis-targeting chimeras (PROTAC) degraders that bind the bromodomain site of SMARCA2 and are published between January 2019-June 2023. A total of 29 applications from 9 different applicants were evaluated. SMARCA2/4 bromodomain inhibitors do not lead to desired effects on cancer proliferation; however, companies have converted bromodomain binders into PROTACs to degrade the protein, with a preference for SMARCA2 over SMARCA4. Selective degradation of SMARCA2 is most likely required to be efficacious in the SMARCA4-deficient setting, while allowing for sufficient safety margin in normal tissues. With several patent applications disclosed recently, interest in targeting SMARCA2 should continue, especially with a selective SMARCA2 PROTAC now in the clinic from Prelude Therapeutics. The outcome of the clinical trials will influence the evolution of selective SMARCA2 PROTACs development.

3 March 2024 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
KRKyle D. Reichl
Kyle D. Reichl
ELEsther C. Y. Lee
Esther C. Y. Lee
AGAriamala Gopalsamy
Ariamala Gopalsamy
The multi-subunit SWI/SNF chromatin remodeling complex is a key epigenetic regulator for many cellular processes, and several subunits are found to be mutated in human cancers. The inactivating mutations of SMARCA4, the ATPase subunit of the complex, result in cellular dependency on the paralog SMARCA2 for survival. This observed synthetic lethal relationship posits targeting SMARCA2 in SMARCA4-deficient settings as an attractive therapeutic target in oncology. This review covers patent literature disclosed during the 2019-30 June 2023 period which claim ATPase inhibitors and PROTAC degraders that bind to the ATPase domain of SMARCA2 and/or SMARCA4. A total of 16 documents from 6 applicants are presented. The demonstration of cellular dependence on SMARCA2 ATPase activity in SMARCA4-deficient settings has prompted substantial research toward SMARCA2-targeting therapies. Although selectively targeting the ATPase domain of SMARCA2 is viewed as challenging, several ATPase inhibitor scaffolds have been disclosed within the last five years. Most early compounds are weakly selective, but these efforts have culminated in the first dual SMARCA2/SMARCA4 ATPase inhibitor to enter clinical trials. Data from the ongoing clinical trials, as well as continued advancement of SMARCA2-selective ATPase inhibitors, are anticipated to significantly impact the field of therapies, targeting SMARCA4-deficient tumors.

12 March 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAriamala Gopalsamy
Ariamala Gopalsamy
KLKitae Lim
Kitae Lim
JEJohn W. Ellingboe
John W. Ellingboe
BMBoris Mitsner
Boris Mitsner
ANAntonia Nikitenko
Antonia Nikitenko
JOJohn O'Connell
John O'Connell